Good day. Thank you for joining us today to discuss the results for LifeMD’s Second Quarter ended June 30, 2022. Joining the call today are Justin Schreiber, Chairman and Chief Executive Officer; and Marc Benathen, Chief Financial Officer of LifeMD. Following management’s prepared remarks, we will open the call for question-and-answer session. I’d like to remind everyone that today’s call is being hosted via webcast and the recording will be made available via the link in today’s press release which is available in the Investor Relations section of the company’s website. Before we begin, I would like to remind everyone that during this call, the company will make a number of forward-looking statements which are subject to numerous risks and uncertainties that may cause the company’s actual results to differ materially from those projected. These risks and uncertainties are described in the company’s 10-K and 10-Q filings and other filings that LifeMD may take with the SEC from time to time. Forward-looking statements made during this call are based on current information available to the company as of today, August 11, 2022. The company assumes no obligation to update or revise any forward-looking statements after today’s call, except as required by law. Also, please note that the management will be discussing certain non-GAAP financial measures that the company believes are important in evaluating LifeMD’s performance. Details on the relationship between these non-GAAP measures to the most comparable GAAP measures and reconciliations thereof can be found in the press release issued earlier today. Finally, I would like to remind everyone that today’s call is being recorded and will be available for replay in the Investor Relations section of the company’s website. Now, I’d like to turn the call over to LifeMD’s CEO, Justin Schreiber. Please go ahead.

Thank you, operator and good afternoon, everyone. Today after the market closed LifeMD issued a press release containing our second quarter results. Additionally, and for the first time ever, we’ve also made available a Q2 supplemental investor highlights presentation, which is available on the LifeMD IR site. I would encourage everyone to download and review this as it summarizes why our second quarter was really what I believe to be a pivotal period in the 2022 transformation of LifeMD. During the second quarter LifeMD made significant progress on several important strategic initiatives to position the company for its next phase of growth. We believe that our growing profitability and expanding margins will be key to our continued transformation from a seller of prescription and OTC products into a rapidly growing and highly profitable telehealth services company. There are a few key accomplishments I’d like to highlight for Q2. First, in the second quarter, we began nationwide direct to patient marketing for our virtual primary care platform. And it’s been extremely successful. We’re seeing some of the best acquisition costs we’ve ever seen. And our technology platform and clinical operations are working beautifully. We’ve also proven that we can cross sell this to our indication specific patient base, which is a very big deal. I’m more confident than ever that this platform will be a very big growth driver in the years to come. Second, we introduced several new telehealth treatment categories to complement our primary care and existing treatment offerings, which we believe has to have significant growth potential. Third, we drove meaningful improvements in our margin performance and profitability. And lastly, we are streamlining our overall company into a telehealth only business through the impending divestiture of work simply. Given our intense focus on profitability, growth of new telehealth…

Thank you, Justin. And good afternoon, everyone. As Justin mentioned, the second quarter of 2022 was a pivotal quarter for the entire company, as we executed upon the early phases of several key strategic initiatives. While the focus on these critical long term areas of growth and profitability will mean our sequential growth will slow for the balance of 2022, our continued execution will position us for heightened growth in the year ahead with strong underlying profitability and be in the best interest of creating long term value for our shareholders. While we continue to reiterate our previous guidance on adjusted EBITDA and consolidated profitability by the fourth quarter 2022, we’re revising our revenue guidance to be in the range of 122 million to 128 million to reflect slower growth from the back half of the year as we focus on these critical long term strategies followed by a return to elevated growth, with consolidated profitability in 2023. Now turning to the results for the second quarter of 2022. revenue in the second quarter totaled a record 30.5 million up 37% as compared to the same quarter a year ago. 93% of total revenues in the second quarter were generated by recurring subscriptions. Telehealth net revenues grew by 41% to 22.3 million while WorkSimpli net revenues grew by 26% to 8.2 million. WorkSimpli revenues grew 27% sequentially as compared to the first quarter, following the execution of several key initiatives we previously discussed. Importantly, WorkSimpli achieved EBITDA margins during the quarter of mid teens for the first time in its history. We expect WorkSimpli’s growth and rising profitability to continue at a rapid pace. On the telehealth side of the business, we increase our active subscriber base by 53% versus prior years ended the quarter with over 168,000 active subscribers.…

Thanks Marc. In summary, while we expect more moderate growth for the balance of the year in our core telehealth business, I’m extremely excited about the future of LifeMD and the role that our company will play in the rapidly evolving telehealth marketplace. The key initiatives that we executed against in the second quarter include nationally launching marketing and beginning to scale our virtual primary care business, diversifying our telehealth revenue, driving meaningful margin and economics and profitability improvements across all our existing telehealth categories and taking steps to streamline our company into a leading telehealth only business through the impending WorkSimpli divestiture. Continued execution against these critical initiatives will cement our future as a leader in telehealth with profitable operations, tremendous organic growth prospects and a strong non dilutive capital base post a potential work simply divestiture to support future investment as we transform from a telehealth products provider to a differentiated full suite telehealth services company. In closing, I would like to thank our entire team, especially our doctors that are treating patients every single day on our platforms for their tireless efforts as they continue to transform the face of medicine, and make amazing health care more accessible, affordable and convenient for our patients. With that, I’d like to open the call for Q&A.

Thank you. [Operator Instructions] And our first question will come from Marc Wiesenberger with B. Riley Securities.

Thank you. Good afternoon. Thanks for taking the questions and appreciate all the additional detailed information. It’s a lot to chew on here. But looking at the supplemental chart showing the progression of adjusted EBITDA can you talk about the dynamics going from April to June? And then some of those puts and takes going from June into the third quarter?

Yes, Mark this is Marc. So the biggest thing starts with advertising. We’ve spent a considerable amount of time in the second quarter after we completed our data analytics infrastructure, which gave us a lot more insight into frankly, every campaign down to every single product subscription likes and pretty much any variable that you’d want to look at being able to really refine a lot of our strategies. Obviously, I can’t get into competitive reasons all but secret behind that, but we exceptionally refined it. And we’re seeing record levels of return on as investment. Now in doing so what happened was we just did some additional dollars for scaling some new verticals, which is really some of the topical pain to sleep obviously VPC and also driving a lot more longer term subscription like that, in turn causes a little bit about short term impact on revenue but really positions the company for accelerated growth in much more profitable economics with quicker payback. So that was the biggest step. The second one is we’re at a point now where we’ve said this all along, going all the way back to the middle of last year, when we said we were going to improve our EBITDA sequentially each quarter. We have the infrastructure to scale the business. I mean, we’ve had that for some time now. And we’re really continuing to see the benefits of the fact that we’ve had, we’re actually going to see some further benefits in our capital expenditures in the coming quarter after we’ve gotten past that initial lift to finish building out the VPC platform and enhanced settlement really an enhancement and growth phase at this point, but that’s where really, a lot of the progress is happening on the telehealth side. Obviously, WorkSimpli has hit their stride, and it’s continuing to grow and we obviously expect to divest somebody in the end of the year but both of the businesses are set up for profitability growth, with the leading reason being that we’ve gotten to a point where we have very strong unit economics that are on a path that continue to get better.

Very helpful. Appreciate that. I think you alluded to, excuse you alluded to it a little bit in the answer, but maybe if you could talk about the specific factors that are contributing to maybe some of the sequential growth that you’re talking about, and I guess is that primarily related to how you are actually allocating the marketing spend and with patients cohorts you’re targeting? And then I guess, what factors contribute to your confidence in the reacceleration of growth that you talked about?

Yes, so the first factor is length of subscription. So at the end of the day, while there’s obviously a benefit to us long term to get people on to six months subscription LifeMD in some cases 12 month subscription like it stretches out to rebuild period. So there’s a short term period where you’re trading people off. And you’re bringing on some of those longer term subscriptions, where you’re not going to have to rebuild every single quarter associated with those longer term subscriptions. We started to really make some of that transition in the first quarter. we saw some impact from timing and the second quarter, we may continue to see for the next couple of quarters related to that, because and then what’s going to come back to us positively is the rebuilding of those subscription links that are a little bit longer. And then the data that we’ve looked at, we are continuing to see higher rebuild rates and retention associated with those longer term subscription length, it’s just that we’re getting to a point of building those up much more significantly this year versus what we did in the beginning of this year and the very end of last year. So that’s on that one. Secondly, on like the product mix piece. One is VPC, we’ve had a really, I think we really hit our stride in the second quarter. And the numbers are still very small, obviously, we expect them to be pretty significant. But just give directionally without giving exact numbers for July, I mean, the revenue in July, well, the numbers are so small, was 4x, the LifeMD today revenue for the VPC, and the numbers are still very small, since the subscriber base is small. But we’re really starting to see a ton of traction after we made certain enhancements to that program launched for [Indiscernible]. So capabilities is totally and obviously improve the overall telehealth offerings that we have there. And then secondly, we know long term that the real success to our business, and frankly, any company in this industry, you cannot be predominantly driven by one category. So we continue to invest in diversifying which means you’re taking away some dollars and short term growth, from just throwing it at your leading area and leading product offering and the company, which short term will be in a little bit slower growth, but we’re seeing tremendous traction and building up some of these new categories that we highlighted on the fall, which we think they’re going to start to get to a very reasonable scale by the end of the year, as will be VPC, which will in turn snowball and make an impact in 2023, both on top and bottom one.

Got it very helpful. Can you talk about how we should think about I guess the unit economics, in light of showing out how the business has kind of been shifting away from ED? How do those unit economics compared to kind of some of the other indications? And as that mix continues, I guess, how do we think about that on impacting the business?

So Mark to be clear we are not, yes Justin can take this.

Yes, Mark, I’d love to comment on that. This is Justin. I think that what we’re seeing with the early data from the VPC platform, but it’s a big enough sample size to draw some early conclusions from. We’re seeing extremely low churn, which is something I’ve always communicated to you and to shareholders that when you give somebody an amazing doctor, it’s the stickiest service on the planet, right. So that’s very encouraging, even with we’re even seeing low churn with people that are joining on the lower priced $15 a month memberships and coming in for say like an initial prescription for something like Pecs love it, like even among those patient populations. We’re seeing low churn, like where churn should be if you Google like where should churn be in a great SAS business or if you look at what that number should be, that’s where we’re at, right single digits. And I think you might see a little bit longer payback on your initial investment and acquisition. But I’m really confident we still have a lot to learn there. But I’m really confident that we’ll be able to see $1 that we spend on acquisition back in our bank account within six months which I think is really, really good. But again, it’s still a little bit too early. We also need to figure out what percentage of the population that’s on, for instance, a $15 month subscription that we can move up to $99 or maybe $49, a month subscription. These are just things that we’re going to learn as we continue to build the business. We’re also working on a lot of highly differentiated offerings, the service offerings that were building around chronic conditions. So a great example could be diabetes. Another example could be treating GERD. Another example could be even something like longevity. So we’re working on a lot of these different, like offerings where you combine a doctor and prescription medications, if appropriate, over the counter products and they’re designed for patients in the population that have different chronic conditions or healthcare goals that we can treat using the platform. And we think over time that these offerings will be really attractive to patients that come in for episodic or urgent treatment to LifeMD.

Got it very helpful. And we’re touching on the VPC patient cohorts. What’s been the mix thus far and how is it evolved in terms of the lower tier versus the upper tier offering?

The mix has been at least 90%, I would say $15 month platform subscribers which are paying per console with a doctor. But some of that, some of the markets just because that’s where we put a lot of our energy initially and we have some we have some really amazing initiatives that are underway right now to really kind of refine and build out the $99 a month offering. We’re really close to launching our prescription drug discount program, which we didn’t mention the call. But another great revenue stream for LifeMD. It’s going to make low cost drug, like really accessible to a lot of those Americans that are on high deductible health plans or uninsured. So I’m really excited about that. And we’re adding like this month we’re taking, we’re going to be launching the symptom checker that we’ve been working on for over a year which I mean, it’s just going to be an awesome product to offer to patients. And so we’re adding a lot of these features which just taken longer than we thought to get live, but they’re highly differentiating for our platform. And I think that, I think they’re going to be important to like really grow in the $99 subscriber base.

And then I’ll just ask one more, and they’ll jump back in. If you could just talk about, I guess, the overall ad market in the second quarter, what you’re seeing thus far into the third quarter? And how do you expect that to play out in term in the rest of the year, and then relating to your ad spend deficiency? Thank you.

I can start and maybe let Marc chime in as well. But we haven’t seen a lot of fluctuation in overall advertising costs. We still see a very competitive environment online, we’ve seen some reduction and CPMs online, but nothing drastic. And we expect like a third quarter to be strong and obviously, like in prior years come towards the end of the year Christmas we typically slow down our ad spend more because the environment gets a lot more difficult. Marc, unless you want to add anything to that.

No, I think that’s all very accurate.

And we will take our next question from David Larsen with BTIG.

So can you just provide a little more color around I think like why product revenue, I think declined on a sequential basis. And I think telehealth net orders decline on a sequential basis? Was that sort of an intentional strategy to focus on higher margin product sales?

Yes, this is Marc. It was exactly what line before for Mark, a lot of it has to do with longer subscription lines, focused on products that are, sorry, subscribers that are a higher margin. With that we have more space that we’re building. We started that focus earlier on in the year. We intensified that focus as we move into the second quarter, we’re going to continue to see some impact from that for the next couple of quarters as we build up a more critical math, longer subscription lines i.e. 6 and 12 month fogs and those begin to start rebuilding next year. But that was an intentional thing. Secondly, we shifted more focus to launching not just launching but also scaling a lot of these new indication so pain, sleep, virtual primary care, which is also a great star. All those added up to what you were seeing and added up to what we called out and we released as was the call today regarding what we expect to see relatively more modest sequential growth over the next couple of quarters, and then obviously rebounding from more aggressive growth, but much more profitable growth going forward next year.

So if you have more lives convert to a subscription model or a longer term subscription model, I guess I’m a little unclear on why that would result in a sequential decline in revenue.

So what happens is when we rebuild along we recognize 100% of that revenue at that time. So if you’re rebill, if you’re on one or three month and you get rebill every month, or every single, every three months, we’re getting more effectively, we can be getting anywhere from one to three rebill next quarter. If you’re on a 6 month, or 12 month, we’re not going to get any rebills from the next quarter, but we’re going to get a lot larger, higher, sum of dollar rebill in the next year. So there’s some timing, as it relates to that, which is what contributes to some of that impact.

And then for PDS Simpli subscribers, I think that there was a pretty good pop sequentially from 1Q to 2Q. Is that correct? It looks like revenue picked up pretty significantly.

That’s correct. Almost all the WorkSimpli subscribers are on point, their two plans, they have month to month and they have annual, most people are month to month. So their revenue growth tends to be pretty closely linked off with our subscribers growth.

And then how is the sale process progressing? And any color you can provide around potential strategic acquirers? Just any.

Yes. Very well said. Very good. We are optimistic about closing a transaction before the end of the year. I can’t get into specifics because we’re actively in the LOI phase. And we’ve got, we’ve received a lot of interest. We’ll leave it at that. And both ourselves and our bankers feel very good about it. Very strong demand. I just I can’t get into specifics, but we’re actively in the process.

And then for CAC, how did that trend in the quarter like from 1Q to 2Q and year-on-year?

Yes. It was down slightly, year-on-year on a blended basis, and it was essentially flat quarter-on-quarter, not much change.

And then assuming, like, if there is a recession, through 2022 and into 1H, 23. How would you expect that to impact a business, if at all?

I don’t think it’s going to impact demand for products and services. If anything, it could drive down CPMs more. So we could see some benefit on the tax side of the business. But we don’t really expect that the impact of demand for the company’s products and services.

Yes David just to add to Marc’s comments. It’s Justin. I think if you look at most of the conditions that we treat, I mean, there are things that need to be treated in a great economic environment or a terrible economic environment. So even if you did see more price sensitivity or some decreases in demand this is something we spend a lot of time looking at. We believe that that’s possible. But we believe that that would also likely be offset by reductions in advertising costs, and we continue to diversify the business to which I think that was one of the most important things for me is that we continue to diversify the business like the primary care businesses, the ultimate diversification. And I think in more difficult economic environment that’s a big plus for LifeMD.

And that will conclude today’s question and answer session. I will turn the conference back over to Mr. Schreiber for any additional or closing remarks.

We don’t have any additional remarks. I just want to thank everybody, all of our shareholders for their continued support. We’re really, really optimistic about future of LifeMD and we’re going to do some great things and continue to build a leadership position in telehealth. Have a nice evening.

And that does conclude today’s conference. Once again thanks everyone for joining us. You may now disconnect.